At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01530 3SBIO
Not Yet Opened 06-05 16:09:12
15.680
-0.300
-1.88%
High16.490
Low15.500
Vol34.98M
Open16.200
D1 Closing15.980
Amplitude6.20%
Mkt Cap39.80B
Tradable Cap39.80B
Total Shares2.54B
T/O552.19M
T/O Rate1.38%
Tradable Shares2.54B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
3SBio (01530) Calls 25 Jun 2026 AGM; Seeks 20% Share-Issue Mandate, 10% Buy-Back Power, HK$0.25 Final Dividend and Auditor Shift to KPMG
3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. The Company's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The Company is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The Company's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The Company mainly operates its businesses in the domestic and overseas markets.